Upadacitinib medical insurance reimbursement policy and patient benefit analysis in 2025

Upadacitinib is a selective JAK1 inhibitor, mainly used to treat immune-related diseases such as moderate to severe active rheumatoid arthritis, ankylosing spondylitis and atopic dermatitis. Since upadatinib was approved for marketing in the country, its clinical application has received widespread attention. From 2025, the drug has been officially included in the national medical insurance catalog, which means that patients can obtain part of the cost reimbursement through medical insurance channels, effectively reducing the financial burden. Although the original price of drugs is still relatively high, medical insurance coverage is undoubtedly a big step towards improving accessibility.

According to current policies, after upadatinib is included in medical insurance, patients can purchase it at medical institutions with prescription qualifications and enjoy a certain proportion of medical insurance reimbursement. The specific reimbursement ratio varies depending on the region, insurance type and designated hospital policy. Generally, the reimbursement ratio of urban employee medical insurance is higher, while the reimbursement ratio of urban and rural residents' medical insurance is relatively low. Some regions also provide special or chronic disease registration policies, which can further increase the reimbursement amount. Patients are advised to consult the local hospital pharmacy or medical insurance department before use to understand the actual reimbursement range and payment amount they can enjoy.

Although medical insurance has brought about economic burden reduction, the price of upadatinib’s original drug after reimbursement is still a certain burden for some patients. Therefore, some patients have also begun to pay attention to foreign generic drugs as an auxiliary option. At present, the generic version produced by Laos Lucius Pharmaceutical Factory has been circulated on the market, and the price is about 500 to 600 yuan per box, which is far lower than the price of the domestic original drug. On the premise that the ingredients of this generic drug are basically the same as those of the original drug, it has a high cost performance, but patients should pay attention to the formality of the channels and drug quality assurance.

In short,2025The implementation of the policy of including upadatinib in medical insurance has greatly alleviated the financial pressure on patients with severe immune diseases and also promoted the widespread use of the drug in clinical practice. However, medical insurance reimbursement is not "completely free" and some costs still need to be paid by the patient themselves. This is still a challenge for some people, especially in the context of long-term medication. Therefore, combining medical insurance policies and guidance on rational drug use, and understanding compliant generic drug alternatives when necessary, is the best way to achieve economic treatment and guaranteed efficacy.

Reference materials:https://www.drugs.com/